🇺🇸 FDA
Patent

US 7776879

Quinuclidine carbamate derivatives and their use as M3 antagonists

granted A61PA61P1/00A61P1/04

Quick answer

US patent 7776879 (Quinuclidine carbamate derivatives and their use as M3 antagonists) held by Almirall, S.A. expires Mon Aug 12 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Almirall, S.A.
Grant date
Tue Aug 17 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 12 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P1/00, A61P1/04, A61P1/06, A61P11/00